Latest Phenethylamines Stories
SAN DIEGO, June 6, 2012 /PRNewswire/ -- Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today it has awarded a $250,000 grant to the WAKE UP! campaign in an effort to combat prescription drug misuse and abuse by teenagers. WAKE UP!, a comprehensive youth program created by The Pain Truth, a 501(c)(3) nonprofit organization, promotes a school and community-based approach to...
Will give law enforcement ability to deal with new drug threat OTTAWA, June 5, 2012 /CNW/ - The Honourable Leona Aglukkaq, Minister of Health, announced today that the Harper Government plans to regulate MDPV, a key ingredient in the illicit drug referred to as "bath salts", under the Controlled Drugs and Substances Act (CDSA). The so-called "bath salts" earned their name because they look like bath salts sold in mainstream drug stores. However, unlike legitimate bath salts,...
NEW YORK, May 31, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials, updates, and intelligence recently reviewed the results presented at the American Thoracic Society (ATS) conference held May 18-23, 2012 in San Francisco, CA. The strong competition to launch the next fixed dose combination (FDC) blockbuster for chronic obstructive pulmonary disease (COPD) was of particular interest to reviewer Jennifer Stacey, Citeline's...
PharmaCo Labs (SupplementsToWeightLoss LLC) today announced that their non-prescription weight loss pill, PhenObestin 37.5, has been proven to help people lose weight as quickly as prescription weight-loss drugs Phentermine and Adipex. This all-natural drug is packed with cutting edge science that helped those people lose weight with no side effects. Germantown, MD (PRWEB) May 29, 2012 More than one million people from around the world have used PhenObestin 37.5 to successfully lose...
CRANFORD, N.J., May 23, 2012 /PRNewswire/ -- Akrimax Pharmaceuticals announced the launch of Suprenza(TM) (phentermine HCl) orally disintegrating tablets (ODT) as a short-term adjunct in the management of exogeneous obesity. Obesity is a major concern in the United States and has been associated with increases in high blood pressure, diabetes, and other diseases. Suprenza(TM) is a sympathomimetic amine anorectic indicated for patients with an initial body mass index (BMI) of greater...
(Ivanhoe Newswire) – A new study shows that critically ill patients were more likely to die if they were taking commonly prescribed antidepressants before being admitted to the intensive care unit (ICU). The study was conducted by researchers at Beth Israel Deaconess Medical Center in Boston and the Massachusetts Institute of Technology in Cambridge. Using a retrospective study, they analyzed the electronic medical records of 10,568 patients to look at in-hospital mortality and mortality...
WASHINGTON, May 14, 2012 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) today applauded Arizona Governor Jan Brewer for signing into law House Bill 2263--anti-meth legislation authored by Representative Heather Carter (R-LD7). Arizona now becomes the 23rd state to adopt real-time, stop-sale technology known as the National Precursor Log Exchange (NPLEx). The proven system--in a process similar to a credit card transaction--allows retailers to automatically...
In the news release, Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD, issued 14-May-2012 by Pearl Therapeutics over PR Newswire, we are advised by the company that the dateline date should read "May 14, 2012" rather than "May 14, 2011" as originally issued inadvertently. The complete, corrected release follows: Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients...
Changes in flies parallel human disorder Perelman School of Medicine at the University of Pennsylvania researchers have discovered a mechanism involving the neurotransmitter dopamine that switches fruit fly behavior from being active during the day (diurnal) to nocturnal. This change parallels a human disorder in which increased agitation occurs in the evening hours near sunset and may also be due to higher than normal dopamine levels in the brain. Sundown syndrome occurs in older people...
REDWOOD CITY, Calif., May 14, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA). PT003 and its components, PT001 (GP MDI) and PT005 (FF MDI) are being developed...
